The Zhitong Finance App learned that on Wednesday, Liquidia (LQDA.US) surged more than 25% in early trading and is now reported at $33.72. According to the news, the company previously announced that it had reached a settlement with United Healthcare in the amount of 380.7 million US dollars, thus ending a long-standing legal dispute over its pulmonary hypertension treatment products. The agreement was announced on Tuesday, settling six pending lawsuits between the parties. Meanwhile, the agreement also allows Liquidia to continue marketing its inhaled formulation YUTREPIA for the treatment of pulmonary hypertension (PAH) without any interruption.

The settlement removed significant legal uncertainty for Liquidia as it expanded Yutrepia's sales and advanced its drug development pipeline. Roger Jeffs, CEO of Liquidia, said the agreement enabled the company to shift its focus from litigation to expand sales of YUTREPIA and develop new treatment options.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.